GlassScriptPhysician profile
Dennis A Mesker
NPI 1467446146
$1,532.09
in general payments reported to CMS, 2019-2025
21 companies · $59.81 in 2025
The $59.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $349 · 2023: $389 · 2024: $594 · 2025: $59.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $642.94 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $196.07 | 2024 | Voquezna |
| Novo Nordisk INC | $160.33 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $65.46 | 2023-2024 | Mounjaro |
| Pfizer INC. | $61.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $50.44 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.36 | 2022 | |
| Inspire Medical Systems, INC. | $43.19 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $35.77 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $29.70 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $28.94 | 2023-2025 | Trelegy Ellipta |
| Abbott Laboratories | $23.88 | 2021 | |
| Dexcom, INC. | $20.02 | 2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $19.56 | 2022 | |
| Astellas Pharma US INC | $18.77 | 2024 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.25 | 2023 | Trintellix |
| Cranial Technologies, INC | $15.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2023 | Camzyos |
| Amgen INC. | $13.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Mesker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.